assembly Bill A5953

2019-2020 Legislative Session

Relates to the availability of buprenorphine in opioid treatment programs

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Assembly Committee

  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

Your Voice

do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

view actions (2)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Jan 08, 2020 referred to alcoholism and drug abuse
Feb 20, 2019 referred to alcoholism and drug abuse

A5953 (ACTIVE) - Details

Law Section:
Mental Hygiene Law
Laws Affected:
Add §32.12, Ment Hyg L
Versions Introduced in Other Legislative Sessions:
2021-2022: A705
2023-2024: A1055

A5953 (ACTIVE) - Summary

Requires all opioid treatment programs to have buprenorphine available for prescription to addicts.

A5953 (ACTIVE) - Bill Text download pdf 


                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  5953

                       2019-2020 Regular Sessions

                          I N  A S S E M B L Y

                            February 20, 2019
                               ___________

Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
  Committee on Alcoholism and Drug Abuse

AN ACT to amend the mental hygiene law, in relation to the  availability
  of buprenorphine in opioid treatment programs

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. The mental hygiene law is amended by adding a  new  section
32.12 to read as follows:
§ 32.12 AVAILABILITY OF BUPRENORPHINE.
  ANY  PROVIDER  OF  SERVICES  OR FACILITY PROVIDING CHEMICAL DEPENDENCE
SERVICES SHALL  HAVE  BUPRENORPHINE  AVAILABLE  TO  BE  ADMINISTERED  TO
ADDICTS.  SUCH CONTROLLED SUBSTANCE SHALL BE ADMINISTERED BY A PHYSICIAN
OR GROUP OF PHYSICIANS PURSUANT TO SUBDIVISION (B) OF SECTION  32.05  OF
THIS ARTICLE.
  § 2. This act shall take effect on the one hundred twentieth day after
it shall have become a law.  Effective immediately, the addition, amend-
ment and/or repeal of any rule or regulation necessary for the implemen-
tation  of  this act on its effective date are authorized to be made and
completed on or before such effective date.





 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD04835-01-9